DePuy Synthes' new spine system earns FDA clearance

Spinal Tech

DePuy Synthes, Johnson and Johnson's orthopedic company, earned FDA 510(k) clearance for the TriALTIS spine system.

The TriALTIS system is a posterior thoracolumbar pedicle screw system with instruments designed for integration with enabling technology, according to an Oct. 9 new release shared with Becker's. It also offers a comprehensive implant portfolio. 

"The TriALTIS™ Spine System will be our premier pedicle screw platform designed to work seamlessly across our entire DePuy Synthes portfolio of enabling technology solutions," Russell Powers, worldwide spine president at DePuy Synthes, said in the release. "Johnson & Johnson MedTech is proud to deliver this exciting innovation that can help facilitate the surgical treatment of spinal degeneration and deformity with the goal to improve fixation, drive better patient outcomes and potentially reduce the clinical and economic burden associated with the current standard of care."

TriALTIS will be available in the U.S. starting in 2024.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers